BMB Reports

생화학분자생물학회 (Korean Society for Biochemistry and Molecular Biology)
권호 표지
DOI QR코드

DOI QR Code

Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches

  • Choi, Hojun (ILIAS Biologics Inc.) ;
  • Shin, Eui-Cheol (Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST))
  • 투고 : 2021.10.10
  • 심사 : 2021.12.03
  • 발행 : 2022.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe COVID-19 exhibit hyper-inflammatory responses characterized by excessive activation of myeloid cells, including monocytes, macrophages, and neutrophils, and a plethora of pro-inflammatory cytokines and chemokines. Accumulating evidence also indicates that hyper-inflammation is a driving factor for severe progression of the disease, which has prompted the development of anti-inflammatory therapies for the treatment of patients with COVID-19. Corticosteroids, IL-6R inhibitors, and JAK inhibitors have demonstrated promising results in treating patients with severe disease. In addition, diverse forms of exosomes that exert anti-inflammatory functions have been tested experimentally for the treatment of COVID-19. Here, we briefly describe the immunological mechanisms of the hyper-inflammatory responses in patients with severe COVID-19. We also summarize current anti-inflammatory therapies for the treatment of severe COVID-19 and novel exosome-based therapeutics that are in experimental stages.

키워드

참고문헌

  1. Zhu N, Zhang DY, Wang WL et al (2020) A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382, 727-733 https://doi.org/10.1056/NEJMoa2001017
  2. Fung TS and Liu DX (2019) Human Coronavirus: hostpathogen interaction. Annu Rev Microbiol 73, 529-557 https://doi.org/10.1146/annurev-micro-020518-115759
  3. Lu RJ, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565-574 https://doi.org/10.1016/s0140-6736(20)30251-8
  4. Wan YS, Shang J, Graham R, Baric RS and Li F (2020) Receptor recognition by the novel Coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS Coronavirus. J Virol 94, e00127-20
  5. Fauci AS, Lane HC and Redfield RR (2020) Covid-19-navigating the uncharted. N Engl J Med 382, 1268-1269 https://doi.org/10.1056/NEJMe2002387
  6. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497-506 https://doi.org/10.1016/s0140-6736(20)30183-5
  7. Richardson S, Hirsch JS, Narasimhan M et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323, 2052-2059 https://doi.org/10.1001/jama.2020.6775
  8. Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033-1034 https://doi.org/10.1016/s0140-6736(20)30628-0
  9. Gustine JN and Jones D (2021) Immunopathology of Hyperinflammation in COVID-19. Am J Pathol 191, 4-17 https://doi.org/10.1016/j.ajpath.2020.08.009
  10. Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054-1062 https://doi.org/10.1016/s0140-6736(20)30566-3
  11. Del Valle DM, Kim-Schulze S, Huang HH et al (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 26, 1636-1643 https://doi.org/10.1038/s41591-020-1051-9
  12. Group RC, Horby P, Lim WS et al (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384, 693-704 https://doi.org/10.1056/NEJMoa2021436
  13. Kim YM and Shin EC (2021) Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med 53, 750-760 https://doi.org/10.1038/s12276-021-00592-0
  14. Mesev EV, LeDesma RA and Ploss A (2019) Decoding type I and III interferon signalling during viral infection. Nat Microbiol 4, 914-924 https://doi.org/10.1038/s41564-019-0421-x
  15. Park A and Iwasaki A (2020) Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27, 870-878 https://doi.org/10.1016/j.chom.2020.05.008
  16. Ribero MS, Jouvenet N, Dreux M and Nisole S (2020) Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog 16, e1008737 https://doi.org/10.1371/journal.ppat.1008737
  17. Choi H and Shin EC (2021) Roles of type I and III interferons in COVID-19. Yonsei Med J 62, 381-390 https://doi.org/10.3349/ymj.2021.62.5.381
  18. Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L and Remuzzi G (2021) Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol 17, 46-64 https://doi.org/10.1038/s41581-020-00357-4
  19. Lee JS, Park S, Jeong HW et al (2020) Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol 5, eabd1554 https://doi.org/10.1126/sciimmunol.abd1554
  20. Galani IE, Rovina N, Lampropoulou V et al (2021) Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol 22, 32-40 https://doi.org/10.1038/s41590-020-00840-x
  21. Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061-1069 https://doi.org/10.1001/jama.2020.1585
  22. Liu J, Liu Y, Xiang P et al (2020) Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 18, 206 https://doi.org/10.1186/s12967-020-02374-0
  23. Carissimo G, Xu W, Kwok I et al (2020) Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nat Commun 11, 5243 https://doi.org/10.1038/s41467-020-19080-6
  24. Zhou Z, Ren L, Zhang L et al (2020) Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 27, 883-890 e882 https://doi.org/10.1016/j.chom.2020.04.017
  25. Chua RL, Lukassen S, Trump S et al (2020) COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol 38, 970-979 https://doi.org/10.1038/s41587-020-0602-4
  26. Liao M, Liu Y, Yuan J et al (2020) Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 26, 842-844 https://doi.org/10.1038/s41591-020-0901-9
  27. Wauters E, Van Mol P, Garg AD et al (2021) Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res 31, 272-290 https://doi.org/10.1038/s41422-020-00455-9
  28. Li J, Guo M, Tian X et al (2021) Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. Med (N Y) 2, 99-112 e117
  29. Middleton EA, He XY, Denorme F et al (2020) Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 136, 1169-1179 https://doi.org/10.1182/blood.2020007008
  30. Zuo Y, Yalavarthi S, Shi H et al (2020) Neutrophil extracellular traps in COVID-19. JCI Insight 5, e138999
  31. Bost P, Giladi A, Liu Y et al (2020) Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 181, 1475-1488 e1412 https://doi.org/10.1016/j.cell.2020.05.006
  32. Ren X, Wen W, Fan X et al (2021) COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell 184, 1895-1913 e1819 https://doi.org/10.1016/j.cell.2021.01.053
  33. Wen W, Su W, Tang H et al (2020) Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov 6, 31
  34. Guo C, Li B, Ma H et al (2020) Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun 11, 3924 https://doi.org/10.1038/s41467-020-17834-w
  35. Williams DM (2018) Clinical pharmacology of corticosteroids. Respir Care 63, 655-670 https://doi.org/10.4187/respcare.06314
  36. Brattsand R and Linden M (1996) Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther 10 Suppl 2, 81-90; discussion 91-82 https://doi.org/10.1046/j.1365-2036.1996.22164025.x
  37. Pulakurthi YS, Pederson JM, Saravu K et al (2021) Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 100, e25719 https://doi.org/10.1097/MD.0000000000025719
  38. Johns M, George S, Taburyanskaya M and Poon YK (2021) A review of the evidence for corticosteroids in COVID-19. J Pharm Pract 897190021998502
  39. Sebba A (2008) Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 65, 1413-1418 https://doi.org/10.2146/ajhp070449
  40. Le RQ, Li L, Yuan W et al (2018) FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23, 943-947 https://doi.org/10.1634/theoncologist.2018-0028
  41. Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 117, 10970-10975 https://doi.org/10.1073/pnas.2005615117
  42. Sciascia S, Apra F, Baffa A et al (2020) Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 38, 529-532
  43. Guaraldi G, Meschiari M, Cozzi-Lepri A et al (2020) Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2, e474-e484 https://doi.org/10.1016/s2665-9913(20)30173-9
  44. Gupta S, Wang W, Hayek SS et al (2021) Association between early treatment with Tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 181, 41-51 https://doi.org/10.1001/jamainternmed.2020.6252
  45. Stone JH, Frigault MJ, Serling-Boyd NJ et al (2020) Efficacy of Tocilizumab in patients hospitalized with Covid-19. N Engl J Med 383, 2333-2344 https://doi.org/10.1056/NEJMoa2028836
  46. Leaf DE, Gupta S and Wang W (2021) Tocilizumab in Covid-19. N Engl J Med 384, 86-87 https://doi.org/10.1056/NEJMc2032911
  47. Salama C, Han J, Yau L et al (2021) Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 384, 20-30 https://doi.org/10.1056/NEJMoa2030340
  48. Rosas IO, Brau N, Waters M et al (2021) Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 384, 1503-1516 https://doi.org/10.1056/NEJMoa2028700
  49. Della-Torre E, Campochiaro C, Cavalli G et al (2020) Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an openlabel cohort study. Ann Rheum Dis 79, 1277-1285 https://doi.org/10.1136/annrheumdis-2020-218122
  50. Lescure FX, Honda H, Fowler RA et al (2021) Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9, 522-532 https://doi.org/10.1016/S2213-2600(21)00099-0
  51. Morinobu A (2020) JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med 43, 148-155 https://doi.org/10.1080/25785826.2020.1770948
  52. Hoang TN, Pino M, Boddapati AK et al (2021) Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. Cell 184, 460-475 e421 https://doi.org/10.1016/j.cell.2020.11.007
  53. Kalil AC, Patterson TF, Mehta AK et al (2021) Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med 384, 795-807 https://doi.org/10.1056/NEJMoa2031994
  54. Titanji BK, Farley MM, Mehta A et al (2021) Use of Baricitinib in patients with moderate to severe Coronavirus disease 2019. Clin Infect Dis 72, 1247-1250 https://doi.org/10.1093/cid/ciaa879
  55. Capochiani E, Frediani B, Iervasi G et al (2020) Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection From RESPIRE protocol. Front Med (Lausanne) 7, 466 https://doi.org/10.3389/fmed.2020.00466
  56. Cao Y, Wei J, Zou L et al (2020) Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol 146, 137-146 e133 https://doi.org/10.1016/j.jaci.2020.05.019
  57. Raposo G and Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200, 373-383 https://doi.org/10.1083/jcb.201211138
  58. Thery C, Zitvogel L and Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2, 569-579 https://doi.org/10.1038/nri855
  59. Pegtel DM and Gould SJ (2019) Exosomes. Annu Rev Biochem 88, 487-514 https://doi.org/10.1146/annurev-biochem-013118-111902
  60. Peng H, Ji W, Zhao R et al (2020) Exosome: a significant nano-scale drug delivery carrier. J Mater Chem B 8, 7591-7608 https://doi.org/10.1039/d0tb01499k
  61. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G and Bonnerot C (2005) Exosomal-like vesicles are present in human blood plasma. Int Immunol 17, 879-887 https://doi.org/10.1093/intimm/dxh267
  62. Pisitkun T, Shen RF and Knepper MA (2004) Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 101, 13368-13373 https://doi.org/10.1073/pnas.0403453101
  63. Michael A, Bajracharya SD, Yuen PS et al (2010) Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis 16, 34-38 https://doi.org/10.1111/j.1601-0825.2009.01604.x
  64. Admyre C, Johansson SM, Qazi KR et al (2007) Exosomes with immune modulatory features are present in human breast milk. J Immunol 179, 1969-1978 https://doi.org/10.4049/jimmunol.179.3.1969
  65. Vojtech L, Woo S, Hughes S et al (2014) Exosomes in human semen carry a distinctive repertoire of small noncoding RNAs with potential regulatory functions. Nucleic Acids Res 42, 7290-7304 https://doi.org/10.1093/nar/gku347
  66. Jafari D, Shajari S, Jafari R et al (2020) Designer exosomes: a new platform for biotechnology therapeutics. BioDrugs 34, 567-586 https://doi.org/10.1007/s40259-020-00434-x
  67. Zipkin M (2019) Exosome redux. Nat Biotechnol 37, 1395-1400 https://doi.org/10.1038/s41587-019-0326-5
  68. Kim J, Song Y, Park CH and Choi C (2021) Platform technologies and human cell lines for the production of therapeutic exosomes. Extracell Vesicles Circ Nucl Acids 2, 3-17
  69. Caplan AI and Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98, 1076-1084 https://doi.org/10.1002/jcb.20886
  70. Baek G, Choi H, Kim Y, Lee HC and Choi C (2019) Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform. Stem Cells Transl Med 8, 880-886 https://doi.org/10.1002/sctm.18-0226
  71. Suh JH, Joo HS, Hong EB, Lee HJ and Lee JM (2021) Therapeutic application of exosomes in inflammatory diseases. Int J Mol Sci 22, 1144 https://doi.org/10.3390/ijms22031144
  72. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A and Bremer N (2020) Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 29, 747-754 https://doi.org/10.1089/scd.2020.0080
  73. Lim SK, Giebel B, Weiss DJ, Witwer KW and Rohde E (2020) Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al. Stem Cells Dev 29, 877-878 https://doi.org/10.1089/scd.2020.0089
  74. Sun D, Zhuang X, Xiang X et al (2010) A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 18, 1606-1614 https://doi.org/10.1038/mt.2010.105
  75. Kim MS, Haney MJ, Zhao Y et al (2016) Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12, 655-664 https://doi.org/10.1016/j.nano.2015.10.012
  76. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S and Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29, 341-345 https://doi.org/10.1038/nbt.1807
  77. Lamichhane TN, Jeyaram A, Patel DB et al (2016) Oncogene knockdown via active loading of small rnas into extracellular vesicles by sonication. Cell Mol Bioeng 9, 315-324 https://doi.org/10.1007/s12195-016-0457-4
  78. Hood JL (2016) Post isolation modification of exosomes for nanomedicine applications. Nanomedicine (Lond) 11, 1745-1756 https://doi.org/10.2217/nnm-2016-0102
  79. Kamerkar S, LeBleu VS, Sugimoto H et al (2017) Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498-503 https://doi.org/10.1038/nature22341
  80. Hood JL, Scott MJ and Wickline SA (2014) Maximizing exosome colloidal stability following electroporation. Anal Biochem 448, 41-49 https://doi.org/10.1016/j.ab.2013.12.001
  81. Tang TT, Wang B, Wu M et al (2020) Extracellular vesicle-encapsulated IL-10 as novel nanotherapeutics against ischemic AKI. Sci Adv 6, eaaz0748 https://doi.org/10.1126/sciadv.aaz0748
  82. Dooley K, McConnell RE, Xu K et al (2021) A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. Mol Ther 29, 1729-1743 https://doi.org/10.1016/j.ymthe.2021.01.020
  83. Yim N, Ryu SW, Choi K et al (2016) Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein-protein interaction module. Nat Commun 7, 12277 https://doi.org/10.1038/ncomms12277
  84. Shalitin D, Yang H, Mockler TC et al (2002) Regulation of Arabidopsis cryptochrome 2 by blue-light-dependent phosphorylation. Nature 417, 763-767 https://doi.org/10.1038/nature00815
  85. Kennedy MJ, Hughes RM, Peteya LA, Schwartz JW, Ehlers MD and Tucker CL (2010) Rapid blue-light-mediated induction of protein interactions in living cells. Nat Methods 7, 973-975 https://doi.org/10.1038/nmeth.1524
  86. Choi H, Kim Y, Mirzaaghasi A et al (2020) Exosome-based delivery of super-repressor IkappaBalpha relieves sepsisassociated organ damage and mortality. Sci Adv 6, eaaz6980 https://doi.org/10.1126/sciadv.aaz6980
  87. Sheller-Miller S, Radnaa E, Yoo JK et al (2021) Exosomal delivery of NF-kappaB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models. Sci Adv 7, eabd3865 https://doi.org/10.1126/sciadv.abd3865
  88. Kim S, Lee SA, Yoon H et al (2021) Exosome-based delivery of super-repressor IkappaBalpha ameliorates kidney ischemia-reperfusion injury. Kidney Int 100, 570-584 https://doi.org/10.1016/j.kint.2021.04.039
  89. Choi H, Choi Y, Yim HY, Mirzaaghasi A, Yoo JK and Choi C (2021) Biodistribution of exosomes and engineering strategies for targeted delivery of therapeutic exosomes. Tissue Eng Regen Med 18, 499-511 https://doi.org/10.1007/s13770-021-00361-0
  90. Imai T, Takahashi Y, Nishikawa M et al (2015) Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles 4, 26238 https://doi.org/10.3402/jev.v4.26238
  91. Kircheis R, Haasbach E, Lueftenegger D, Heyken WT, Ocker M and Planz O (2020) NF-kappaB pathway as a potential target for treatment of critical stage COVID-19 patients. Front Immunol 11, 598444 https://doi.org/10.3389/fimmu.2020.598444
  92. Hariharan A, Hakeem AR, Radhakrishnan S, Reddy MS and Rela M (2021) The role and therapeutic potential of nf-kappa-b Pathway in Severe COVID-19 patients. Inflammopharmacology 29, 91-100 https://doi.org/10.1007/s10787-020-00773-9